Affimed Analyst Ratings
Affimed Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 819.96% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/08/2023 | 1003.96% | Berenberg | → $6 | Assumes | → Buy |
| 06/05/2023 | 819.96% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 05/24/2023 | 1003.96% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/27/2023 | 1187.95% | Wells Fargo | → $7 | Assumes | → Overweight |
| 03/24/2023 | 83.99% | Stifel | $2 → $1 | Maintains | Hold |
| 03/24/2023 | 1003.96% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 12/12/2022 | 1187.95% | Wells Fargo | $8 → $7 | Maintains | Overweight |
| 12/12/2022 | 1003.96% | Piper Sandler | $7 → $6 | Maintains | Overweight |
| 12/12/2022 | 1003.96% | SVB Leerink | $10 → $6 | Maintains | Outperform |
| 12/12/2022 | 1003.96% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 10/10/2022 | 267.99% | Stifel | $9 → $2 | Downgrades | Buy → Hold |
| 06/23/2022 | 1555.93% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 03/31/2022 | 1187.95% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 2107.91% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 10/21/2021 | 1739.93% | Truist Securities | → $10 | Initiates Coverage On | → Buy |
| 10/12/2021 | 2107.91% | SVB Leerink | $13 → $12 | Maintains | Outperform |
| 09/30/2021 | 2107.91% | Stifel | → $12 | Initiates Coverage On | → Buy |
| 03/31/2021 | 2659.89% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 03/24/2021 | 2659.89% | Wells Fargo | $10 → $15 | Maintains | Overweight |
| 03/11/2021 | 2475.9% | SVB Leerink | $9 → $14 | Maintains | Outperform |
| 11/11/2020 | 1555.93% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 06/24/2020 | 1371.94% | SVB Leerink | $7 → $8 | Maintains | Outperform |
| 03/28/2019 | 1371.94% | SVB Leerink | → $8 | Initiates Coverage On | → Outperform |
| 08/28/2018 | 635.97% | Jefferies | $1.8 → $4 | Upgrades | Hold → Buy |
| 08/28/2018 | 819.96% | BMO Capital | $4 → $5 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月11日 | 819.96% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 2023/08/08 | 1003.96% | 贝伦伯格 | →$6 | 假设 | →购买 |
| 06/05/2023 | 819.96% | HC Wainwright公司 | $6→$5 | 维护 | 买 |
| 2023年05月24日 | 1003.96% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 03/27/2023 | 1187.95% | 富国银行 | →$7 | 假设 | →超重 |
| 03/24/2023 | 83.99% | Stifel | $2→$1 | 维护 | 保持 |
| 03/24/2023 | 1003.96% | HC Wainwright公司 | →$6 | 重申 | →购买 |
| 2022年12月12日 | 1187.95% | 富国银行 | $8→$7 | 维护 | 超重 |
| 2022年12月12日 | 1003.96% | 派珀·桑德勒 | $7→$6 | 维护 | 超重 |
| 2022年12月12日 | 1003.96% | SVB Leerink | $10→$6 | 维护 | 跑赢大盘 |
| 2022年12月12日 | 1003.96% | HC Wainwright公司 | →$6 | 开始承保 | →购买 |
| 2022年10月10日 | 267.99% | Stifel | $9→$2 | 评级下调 | 购买→Hold |
| 2022/06/23 | 1555.93% | SVB Leerink | $10→$9 | 维护 | 跑赢大盘 |
| 03/31/2022 | 1187.95% | 派珀·桑德勒 | →$7 | 开始承保 | →超重 |
| 02/23/2022 | 2107.91% | 康托·菲茨杰拉德 | →$12 | 开始承保 | →超重 |
| 2021/10/21 | 1739.93% | Truist证券 | →$10 | 开始承保 | →购买 |
| 10/12/2021 | 2107.91% | SVB Leerink | $13→$12 | 维护 | 跑赢大盘 |
| 09/30/2021 | 2107.91% | Stifel | →$12 | 开始承保 | →购买 |
| 03/31/2021 | 2659.89% | 瑞士信贷 | →$15 | 开始承保 | →跑赢大盘 |
| 03/24/2021 | 2659.89% | 富国银行 | $10→$15 | 维护 | 超重 |
| 03/11/2021 | 2475.9% | SVB Leerink | $9→$14 | 维护 | 跑赢大盘 |
| 11/11/2020 | 1555.93% | SVB Leerink | $8→$9 | 维护 | 跑赢大盘 |
| 06/24/2020 | 1371.94% | SVB Leerink | $7→$8 | 维护 | 跑赢大盘 |
| 2019/03/28 | 1371.94% | SVB Leerink | →$8 | 开始承保 | →跑赢大盘 |
| 2018年08月28日 | 635.97% | 杰富瑞 | $1.8→$4 | 升级 | 持有→购买 |
| 2018年08月28日 | 819.96% | 蒙特利尔银行资本 | $4→$5 | 维护 | 跑赢大盘 |
What is the target price for Affimed (AFMD)?
阿基米德(AFMD)的目标价是多少？
The latest price target for Affimed (NASDAQ: AFMD) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $5.00 expecting AFMD to rise to within 12 months (a possible 819.96% upside). 12 analyst firms have reported ratings in the last year.
HC Wainwright&Co.于2023年8月11日报道了Affimed(纳斯达克代码：AFMD)的最新目标价。这家分析公司将目标价定为5美元，预计AFMD将在12个月内上涨(可能上涨819.96%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Affimed (AFMD)?
AFMD的最新分析师评级是多少？
The latest analyst rating for Affimed (NASDAQ: AFMD) was provided by HC Wainwright & Co., and Affimed reiterated their buy rating.
分析师对Affimed(纳斯达克代码：AFMD)的最新评级由HC Wainwright&Co.提供，Affimed重申其买入评级。
When is the next analyst rating going to be posted or updated for Affimed (AFMD)?
Affimed(AFMD)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Affimed的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Affimed的上一次评级是在2023年8月11日提交的，所以你应该预计下一次评级将在2024年8月11日左右提供。
Is the Analyst Rating Affimed (AFMD) correct?
分析师评级确认(AFMD)正确吗？
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price Affimed (AFMD) is trading at is $0.54, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Affimed(AFMD)评级被重申，目标价在0.00美元至5.00美元之间。目前Affimed(AFMD)的交易价格为0.54美元，在分析师的预测范围内。